Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
Objective. Bone secondary localizations from metastatic castration-resistant prostate cancer are associated with an increase in mortality and a reduction in the patient’s quality of life. Radium-223 is a targeted alpha-therapy approved for the treatment of mCRPC (metastatic castration resistant pro...
Main Authors: | Viviana Frantellizzi, Julia Lazri, Mariano Pontico, Arianna Pani, Giuseppe De Vincentis |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2020-10-01
|
Series: | Archivio Italiano di Urologia e Andrologia |
Subjects: | |
Online Access: | https://www.pagepressjournals.org/index.php/aiua/article/view/8854 |
Similar Items
-
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
by: Axel Heidenreich, et al.
Published: (2019-01-01) -
Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment
by: Frantellizzi Viviana, et al.
Published: (2019-12-01) -
Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
by: Kim van der Zande, et al.
Published: (2021-08-01) -
Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
by: Jeroen H. A. Creemers, et al.
Published: (2021-05-01) -
RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)